PHARMACOVIGILANCE IN CLINICAL RESEARCH: PAST, PRESENT AND FUTURE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 4
Abstract
The growing clinical research after the product patents rights for the pharmaceutical industries as per the trade related aspects of intellectual property rights agreement and adverse drug reaction monitoring of the marketed drugs have raised many ethical and regulatory issues regarding the promotion of new drugs in Indian markets. It becomes vital to understand the history, growth and evolution of the regulatory aspects of drugs which are handled by multiple Ministries and Departments of the Government of India. Although amendment to Schedule Y, registration of Ethics committee, registration of Clinical Trials, Speeding up review process, Pharmacovigilance (PhV) programme for India and Inspection of clinical trial sites have been started by the various regulatory agencies. India’s growing partaking in multinational trials, this artifact explores potential areas of Indian pharmacovigilance, requiring reform and provides recommendations for building a robust safety reporting system. (1) Despite global focus on Development Safety Update Report, local regulators are not yet insistent on real-time update of a drug's cumulative safety profile. Issues like reporting requirements for generic trials, pregnancy reporting and lenient timeline for death/life-threatening events need attention. (2)
Authors and Affiliations
Chauhan Pratibha, Yadav Ashish, Kirodian Babita
Keywords
Related Articles
- EP ID EP337075
- DOI 10.22270/ijdra.v4i4.188
- Views 120
- Downloads 0
QUALITY STANDARDS FOR MEDICAL DEVICES
Formerly with more augmented disabilities, Medical devices have become decisive device in many circumstances. As these are more perilous, the manufacturer should endow with an ideal medical device in aspects of safety &...
COMPARISON OF GLOBAL REGULATORY GUIDELINES FOR AVAILABILITY OF DIFFERENT BIOWAIVER PROVISIONS AND APPLICATION REQUIREMENTS OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) BASED BIOWAIVER.
To waive a complete and systemic Bioequivalence (BE) study, Biowaiver or Request for a Biowaiver is a fast track approach to boost the drug development process. Over the past three-four years the Biowaiver market shows g...
COMMON DEFICIENCIES RAISED BY VARIOUS REGULATORY AGENCIES
Timely Product registration is a challenge in today’s scenario. Regulatory agencies are keen in assessing CTD sections like redefining starting material of Drug substance manufacturing, Pharmaceutical development, impuri...
A review on ANDA submission requirements for Generic drugs: “Paragraph IV certification” as per FDA CDER guidelines
USFDA is one the most regulated agencies wherein the submission process is most critical. The study depends on how to submit ANDA application as per FDA, CDER guidelines in paragraph IV submission in Federal Food, Drug,...
Pre-filled syringes in developed and developing region: An insight into Regulatory considerations
A Pre-filled syringe is a disposable syringe that is supplied already loaded with the substance to be injected. It is a unit dose of parenteral medication to which a needle has been fixed by a producer. They are small wh...